Search
2025
2024
2023
-
Mar 21, 2025
YolTech Therapeutics Announces GMP Manufacturing Facility Expansion to Support Gene Editing Therapy Commercial ManufacturingRead More
-
Mar 11, 2025
YolTech Therapeutics Announces Positive Clinical Results for YOLT-201, an Investigational In Vivo Gene Editing Therapy for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Read More
-
Feb 25, 2025
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)Read More
-
Dec 21, 2024
YolTech Completes Dose Escalation in YOLT-201 Phase I TrialRead More
-
Nov 05, 2024
YolTech and East China Normal University Publish Breakthrough Study on In Vivo Genome Editing for Blood DisordersRead More
